Tirzepatide 120mg

Description

Strength: 120mg
CAS: 2023788-19-2
Chemical Formula: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight: 4813.48 g/mol
Peptide Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20-linker)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
Synonyms: P1206, LY3298176, tirzepatida, tirzepatidum, OYN3CCI6QE
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

Tirzepatide is a synthetic 39-amino-acid peptide studied for its dual agonist activity at the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP-1) receptors. In experimental settings, this dual incretin signaling profile is examined for its role in glucose homeostasis, insulin dynamics, and energy-balance regulation.

This research-grade formulation is supplied exclusively for laboratory research purposes and is NOT intended for clinical, diagnostic, therapeutic, or any human use.

Tirzepatide 120 mg is supplied as a pharmaceutical-grade lyophilized peptide in sterile vials. Research programs that buy tirzepatide peptide employ this material in controlled laboratory studies focused on incretin biology and metabolic signaling pathways.

Tirzepatide peptide is a structurally modified incretin analog engineered to support receptor selectivity, biased signaling, and extended systemic exposure in experimental models.

• Peptide length: 39 amino acids
• Peptide classification: Dual GIPR / GLP-1R agonist
• Amino acid sequence (modified): Y-Aib-E-G-T-F-T-S-D-Y-S-I-Aib-L-D-K-I-A-Q-K(γ-Glu-AEEA-AEEA-C20 diacid)-A-F-V-Q-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S-NH₂
• Structural modifications:
  • α-Aminoisobutyric acid (Aib) at positions 2 and 13
  • C20 fatty diacid conjugate at Lys20 via γ-glutamic acid + bis-AEEA linker
  • C-terminal L-serinamide
• Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular weight: 4810.52 Da
• PubChem CID: 156588324
• Receptor selectivity: GIPR-preferential with GLP-1R activity
• Signaling profile: Biased agonism favoring cAMP pathways
• Format: High-purity lyophilized peptide
• Regulatory status: For laboratory research use only. Supplied to qualified researchers who order tirzepatide peptide through authorized sources

In experimental systems, tirzepatide is studied for coordinated incretin receptor signaling, rather than isolated receptor activation.

Mechanistic endpoints commonly evaluated include:

• Glucose-dependent insulin secretion in pancreatic β-cells
• Reduction of β-cell apoptosis under metabolic stress
• Glucagon modulation, dependent on ambient glucose levels
• Biased agonism, with preferential cAMP signaling over β-arrestin recruitment
• Gastric motility and satiety regulation, assessed through vagal signaling and central nervous system pathways
• Energy metabolism effects, including adipose tissue insulin sensitivity and triglyceride regulation
• Albumin binding via C20 fatty diacid conjugation, supporting extended half-life (~5 days) in animal models

Tirzepatide is supplied exclusively for laboratory research and may be utilized in studies including:

• Pancreatic islet and β-cell function assays
• Incretin receptor pharmacology, including cAMP assays and β-arrestin recruitment
• Glucose homeostasis models such as OGTT, IPGTT, and insulin tolerance testing
• Appetite regulation and CNS-mediated energy balance
• Adipose tissue metabolism and insulin signaling cascades
• Lipid metabolism and cardiometabolic risk marker evaluation
• Renal function and metabolic nephroprotection studies
• Biased agonism and structure–function relationship analysis
• Combination pharmacology and drug–interaction research under controlled conditions

Tirzepatide contains a C20 fatty diacid conjugate, which is sensitive to oxidation, hydrolysis, and aggregation.

Lyophilized (Unopened)

• –80 °C: Preferred for 1+ year storage
• –20 °C: Stable for 6–24 months
• 2–8 °C: Up to 4 weeks for active research use
• Store sealed, protected from light and moisture

Reconstituted Solution

• Maintain at 2–8 °C
• Optimal use within 24–72 hours
• May extend to 7 days if sterile and protected from light
• Avoid freeze–thaw cycles
• Minimize temperature fluctuations

Visual Inspection Guidance

• Pale yellow coloration: Acceptable and associated with fatty-acid conjugation
• Brown or dark discoloration: Indicates oxidative degradation
• Cloudiness or particulates: Suggest aggregation or contamination

A 120 mg research vial may correspond to approximately 8–48 clinical doses, depending on dose level. This vial format is not a clinical dosing preparation and must not be interpreted as such.

References

https://pubmed.ncbi.nlm.nih.gov/36050763/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9354517/

https://pmc.ncbi.nlm.nih.gov/articles/PMC10614386/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12046485/

https://www.ncbi.nlm.nih.gov/books/NBK585056/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.